Key result
Baroreflex activation therapy shows potential for resistant hypertension, but definitive efficacy and safety evidence remains lacking.
Why the study?
Despite an arsenal of antihypertensive medications, blood pressure values cannot be corrected in a substantial portion of patients with resistant hypertension.
Does baroreflex activation therapy reduce blood pressure in patients with resistant hypertension?
Does baroreflex activation therapy reduce blood pressure in patients with resistant hypertension?
Baroreflex activation therapy is an emerging, device-based approach that shows potential in lowering blood pressure for resistant hypertension, but definitive evidence is required before widespread adoption.
Baroreflex activation therapy should not yet change practice in resistant hypertension; leaves open the need for definitive randomized trials on efficacy and safety.
Resistant hypertension has become an interesting and controversial topic in the last decade. According to the European Guidelines for the management and treatment of hypertension, resistant hypertension is defined as the lack of blood pressure control despite the control of risk factors and good compliance with a treatment with at least three antihypertensives in the maximum tolerated doses, one of which is a diuretic, at patients in whom possible causes of secondary arterial hypertension were excluded. In the official position of the AHA (American Heart Association) on this subject, resistant HTN is considered as HTN uncontrolled with three antihypertensive drugs or HTN controlled but requiring at least four drugs. Although the medical world has a complex arsenal of antihypertensive preparations, with them it is not possible to correct the values in a good part of the patients. A solution would be the development and study of the effectiveness of baroreflex activation therapy.
No takes yet. Share an insight, caveat, or question.
Corsun et al. (2023) conducted a review in Resistant hypertension. Baroreflex activation therapy was evaluated. Baroreflex activation therapy remains a potential continuous study option for managing resistant hypertension, though incontestable evidence regarding its clinical efficacy and safety is still lacking.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: